| Literature DB >> 26060398 |
Abstract
Nanoparticles (NPs) present in the environment and in consumer products can cause immunotoxic effects. The immune system is very complex, and in vivo studies are the gold standard for evaluation. Due to the increased amount of NPs that are being developed, cellular screening assays to decrease the amount of NPs that have to be tested in vivo are highly needed. Effects on the unspecific immune system, such as effects on phagocytes, might be suitable for screening for immunotoxicity because these cells mediate unspecific and specific immune responses. They are present at epithelial barriers, in the blood, and in almost all organs. This review summarizes the effects of carbon, metal, and metal oxide NPs used in consumer and medical applications (gold, silver, titanium dioxide, silica dioxide, zinc oxide, and carbon nanotubes) and polystyrene NPs on the immune system. Effects in animal exposures through different routes are compared to the effects on isolated phagocytes. In addition, general problems in the testing of NPs, such as unknown exposure doses, as well as interference with assays are mentioned. NPs appear to induce a specific immunotoxic pattern consisting of the induction of inflammation in normal animals and aggravation of pathologies in disease models. The evaluation of particle action on several phagocyte functions in vitro may provide an indication on the potency of the particles to induce immunotoxicity in vivo. In combination with information on realistic exposure levels, in vitro studies on phagocytes may provide useful information on the health risks of NPs.Entities:
Keywords: cytokines; immunotoxicity; nitric oxide generation; phagocytes; phagocytosis; respiratory burst
Mesh:
Substances:
Year: 2015 PMID: 26060398 PMCID: PMC4454219 DOI: 10.2147/IJN.S83068
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Receptors linked to main functions of phagocytes.
Note: Activation of these receptors regulates macrophage function, which can be evaluated by a panel of in vitro assays.
Abbreviations: CD14, lipopolysaccharide-binding protein receptor; LPS, lipopolysaccharide; IFN, interferon; TNF, tumor necrosis factor; MHC, major histocompatibility complex; LFA, lymphocyte function-associated antigen; ICAM, intercellular adhesion molecule; Ig, immunoglobulin; NO, nitric oxide.
Mechanisms of interference between nonbiodegradable NPs and in vitro assays
| Mechanism | Assay(s) | Particle(s) | Reference(s) |
|---|---|---|---|
| Absorbance | Hemolysis | Au, C60 | |
| LAL | Au, C60 | ||
| MTT | Au, CB, C60, Qdots, Ag, AgO, iron oxide, SWCNT | ||
| WST-1 | Iron oxide | ||
| MTS | Al, Qdots | ||
| LDH | Au, SiO2, iron oxide, CeO2 | ||
| Light scattering | MTT, ATP | Carbon nanodiamonds | |
| Dye absorption | MTT | SWCNT, CB, Al, iron oxide | |
| NR | CB, SWCNT, C60, Si, TiO2 | ||
| AB, AK | SWCNT | ||
| CB, WST-1 | SWCNT | ||
| Enzyme inactivation/inhibition | LDH | Cu, Ag | |
| LDH | ZnO | ||
| LDH | Si, Au, Qdots | ||
| LDH | Au | ||
| AK | PS | ||
| Enzyme adsorption | LDH | Cu, Qdots, TiO2 | |
| Reduction/enzymatic activity | MTT | Si, SWCNT, C60, TiO2 | |
| AB | Si | ||
| AK | SWCNT | ||
| Prevention of reduction | MTT | Zn | |
| Oxidation | H2DCF | CB | |
| Hemoglobin | Iron oxide | ||
| Protein binding | Cytokines | CB, SWCNT, iron oxide, Cu, SiO2, Al2O3, CeO2, NiO2, TiO2 | |
| Increase enzymatic activity | LAL | Iron oxide | |
| Hemoglobin | PS, SWCNT | ||
| Physical interaction | TB, calcein AM, live/dead | SWCNT, C60, CB, Qdots | |
| COMET | Ge | ||
| Quenching of fluorescence | H2DCF | CB, SiO2, SiO2-iron | |
| LDH | CB, SWCNT, C60, Qdots | ||
| Calcein AM/EthD-1 | CB, SWCNT | ||
| Increase of fluorescence | H2DCF | Au, iron oxide, TiO2, C60, SiO2, CB, SWCNT | |
| PI | Qdots, PS | ||
| Calcein AM/EthD-1 | CB, iron oxide | ||
| AB | CB, SWCNT, TiO2, Qdots | ||
| Resazurin | CoO | ||
| COMET | TiO2, CuO | ||
| Increase of luminescence | Phagocytosis | Qdots | |
| ATP | SiO2 | ||
| Quenching of luminescence | Phagocytosis | Au | |
| Aggregation | Platelet aggregation | Au, C60 |
Abbreviations: NPs, nanoparticles; Au, gold; C60, C60 fullerenes; LAL, limulus amebocyte lysate; CB, carbon black; Qdots, CdSe quantum dots; Ag, silver; SWCNT, single-walled carbon nanotube; WST-1, water soluble tetrazolium salt; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); Al, aluminum; LDH, lactate dehydrogenase; SiO2, silica; CeO2, cerium oxide; ATP, adenosine triphosphate; NR, neutral red; TiO2, titanium dioxide; AB, alamarBlue; AK, adenylate kinase; Cu, copper; ZnO, zinc oxide; PS, polystyrene; Zn, zinc; H2DCF, dihydrodichlorofluorescein; Al2O2, aluminum oxide; NiO2, nickel oxide; TB, trypan blue; AM, acetoxymethylester; Ge, germanium; EthD-1, ethidium homodimer 1; PI, propidium iodide; CoO, cobalt oxide; CuO, copper (II) oxide.
Effects of NPs after inhal, IN, IG, IP, IV, oral, oroph, and SC application, and ID and IT in normal animals and in animal models (Model)
| Particle | Size (nm) | Application | Model | Effect | Reference(s) |
|---|---|---|---|---|---|
| Polystyrene | 25–50 | IT | Lung inflammation | ||
| 68 | IT | Coupled antigen | Stimulation of antigen response | ||
| 40 | ID | OVA | Increased sensitization | ||
| 58 | IT | OVA | Increased sensitization | ||
| 100 | SC | OVA | Increased sensitization | ||
| 20, 50, 100 | ID | Atopic dermatitis | Aggravation of inflammation | ||
| SWCNT | 1–2 | Oroph | Decreased lung clearance of bacteria | ||
| 1–2 | IT | Proinflammatory cytokine secretion | |||
| 1–2 | IT | OVA | Increased sensitization | ||
| 1–2 | Inhal, SC | OVA | Increased sensitization | ||
| 1–2 | IT | LPS | Aggravation of inflammation | ||
| DWCNT | 2 | IN | Proinflammatory cytokine secretion | ||
| MWCNT | 20–30 | SC | Proinflammatory cytokine secretion | ||
| 10–20 | Inhal | Proinflammatory cytokine secretion | |||
| 12.5–25 | Oroph | Lung inflammation | |||
| 20–30 | IT | Proinflammatory cytokine secretion | |||
| 25 | IV | Proinflammatory cytokine secretion | |||
| 90 | IP | Proinflammatory cytokine secretion | |||
| 67 | IT | OVA | Increased sensitization | ||
| 10–50 | Inhal, SC | OVA | Increased sensitization | ||
| 30–50 | Inhal | OVA | Increased sensitization | ||
| 67 | IT | LPS | Aggravation of lung inflammation | ||
| 10–50 | IT | LPS | Aggravation of inflammation | ||
| Ag | 10 | ID | Erythema | ||
| 18 | Inhal | Lung inflammation | |||
| 18 | Inhal | Lung inflammation | |||
| 20 | IV | Suppressed immune response to KLH immunization | |||
| 22, 42, 71 | Oral | Increased TGF-β levels | |||
| 52 | IT | Proinflammatory cytokine secretion | |||
| 33 | IN | OVA | Increased sensitization | ||
| Au | 50 | IT | Lung inflammation | ||
| 50, not 10 | IP | Proinflammatory cytokine secretion | |||
| 21 | IP | Anti-inflammatory action in adipose tissue | |||
| 15 | Oroph | TDI | Aggravation of asthma | ||
| 5, 15 | IP | IL-1β inflammation | Decrease of inflammation | ||
| Iron oxide | 5.3 | IT | Lung inflammation and allergic response | ||
| 20 | IV | Proinflammatory cytokine secretion | |||
| 36 | IT | Lung inflammation and cytokine secretion | |||
| 58 | IV | Decreased OVA-specific antigen production | |||
| 43 | IT | OVA | Increased sensitization | ||
| 35 | IT | OVA | Increased sensitization | ||
| SiO2 | 10 | IT | Lung inflammation | ||
| 12 | IP | Proinflammatory cytokine secretion | |||
| 30, 70 | IP | Proinflammatory cytokine secretion | |||
| 15 | IV | Proinflammatory cytokine secretion | |||
| 70 | IV | Proinflammatory cytokine secretion | |||
| 30, 70, 100 | ID | Atopic dermatitis | Aggravation of inflammation | ||
| 10–20 | IT | OVA | Increased sensitization | ||
| TiO2 | 2–5 | Inhal | Lung inflammation | ||
| 5 | IP | Proinflammatory cytokine secretion | |||
| 5.5 | IG | Infiltration of immune cells in spleen | |||
| 8–10 | IN | Lung inflammation | |||
| 20 | ID, not oral | Immune activation | |||
| 20 | Inhal | Lung inflammation | |||
| 20 | IT | Lung inflammation | |||
| 25 | IT | Proinflammatory cytokine secretion | |||
| 25 | IT | Lung inflammation | |||
| 15, 28 | IT | Lung inflammation | |||
| 30–40 | IT | Lung inflammation | |||
| 66 | Oral | Proinflammatory cytokine secretion | |||
| 20 | IG | Proinflammatory and allergic cytokine secretion | |||
| 14, 29 | Inhal | OVA | Increased sensitization | ||
| 15 | Oroph | TDI | Aggravation of asthma | ||
| 20 | IP | LPS | Aggravation of lung inflammation | ||
| 28 | Inhal | OVA | Increased sensitization | ||
| ZnO | 10 | Inhal | Lung inflammation | ||
| <10 | IT | Lung inflammation | |||
| 21 | Oral | No effect on oral tolerance to OVA | |||
| 21 | IP | OVA | Increased sensitization | ||
| 55 | IP | OVA | Increased sensitization |
Abbreviations: NPs, nanoparticles; inhal, inhalation; IN, intranasal; IG, intragastral; IP, intraperitoneal; IV, intravenous; oroph, oropharyngeal; SC, subcutaneous; ID, intradermal; IT, intratracheal instillation; OVA, ovalbumin; SWCNT, single-walled carbon nanotube; LPS, lipopolysaccharide; DWCNT, double-walled carbon nanotube; MWCNT, multiwalled carbon nanotube; Ag, silver; TGF, transforming growth factor; KLH, keyhole limpet hemocyanin; Au, gold; TDI, toluene diisocyanate; IL, interleukin; SiO2, silica; TiO2, titanium dioxide; ZnO, zinc oxide.
Immune effects in isolated phagocytes, either after in vivo treatment with nanoparticles (ex vivo) or by in vitro treatment
| Particle | Effects
| |
|---|---|---|
| Ex vivo | In vitro | |
| Polystyrene | Proinflammatory cytokine secretion | |
| Increased respiratory burst | ||
| Neutrophilic granulocyte activation | ||
| MWCNT | Proinflammatory cytokine secretion | |
| Inhibition of DC maturation | ||
| SWCNT | Decreased chemotaxis | |
| Decreased phagocytosis | ||
| Ag | Proinflammatory cytokine secretion after IT application | Proinflammatory cytokine secretion |
| Proinflammatory cytokine secretion after inhalation | Decreased phagocytosis | |
| Proinflammatory cytokine secretion after oropharyngeal application | Increased respiratory burst | |
| Proinflammatory cytokine secretion after oral application | Decreased NO production | |
| Neutrophilic granulocyte activation | ||
| Au | Proinflammatory cytokine secretion | |
| No increased cytokine secretion | ||
| No effect on DC maturation, no activation | ||
| Iron oxide | Proinflammatory cytokine secretion after IT application | Proinflammatory cytokine secretion |
| Upon LPS challenge, decreased cytokine secretion after IT application | Decreased phagocytosis | |
| Increased NO production with and without | ||
| LPS challenge | ||
| No effect on DC maturation | ||
| SiO2 | Increased NO production after IT application | Proinflammatory cytokine secretion |
| Activation of DC | ||
| TiO2 | Proinflammatory cytokine secretion after IT application | Proinflammatory cytokine secretion |
| Proinflammatory cytokine secretion after IG application | Decreased chemotaxis | |
| Decreased phagocytosis | ||
| Increased NO production after IT application | Increased respiratory burst | |
| Decreased chemotaxis after IT application | Activation of DC | |
| ZnO | Decrease of cytokine secretion after oral application | Proinflammatory cytokine secretion |
| Proinflammatory cytokine secretion after IT application | Decreased chemotaxis | |
| Proinflammatory cytokine secretion after inhalation | Decreased phagocytosis | |
| Increased respiratory burst | ||
Abbreviations: MWCNT, multiwalled carbon nanotube; DC, dendritic cells; SWCNT, single-walled carbon nanotube; Ag, silver; IT, intratracheal instillation; NO, nitric oxide; Au, gold; LPS, lipopolysaccharide, SiO2, silica; TiO2, titanium dioxide; IG, intragastral; ZnO, zinc oxide.
Overview of nanoparticle actions on phagocyte functions
| Particles | Cytokine secretion
| Chemotaxis
| Phagocytosis
| Respiratory burst
| NO generation
| Degranulation
| DC maturation
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ex vivo | In vitro | Ex vivo | In vitro | Ex vivo | In vitro | Ex vivo | In vitro | Ex vivo | In vitro | Ex vivo | In vitro | Ex vivo | In vitro | |
| Polystyrene | ↑ | ↑ | ↑ | |||||||||||
| MWCNT | ↑ | ↓ | ||||||||||||
| SWCNT | ↓ | ↓ | ||||||||||||
| Ag | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ||||||||
| Au | ↑ − | – | ||||||||||||
| Iron oxide | ↑ | ↑ | ↓ | ↑ | – | |||||||||
| SiO2 | ↑ | ↑ | ↑ | |||||||||||
| TiO2 | ↑ | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | |||||||
| ZnO | ↑ ↓ | ↑ | ↓ | ↓ | ↑ | |||||||||
Notes: Red arrow: increase; black arrow: decrease; –: no change.
Abbreviations: NO, nitric oxide; DC, dendritic cell; MWCNT, multiwalled carbon nanotube; SWCNT, single-walled carbon nanotube; Ag, silver; Au, gold; SiO2, silica; TiO2, titanium dioxide; ZnO, zinc oxide.